Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Juniper Pharmaceuticals Inc (NASDAQ: JNP) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Juniper Pharmaceuticals Inc (NASDAQ: JNP) concerning whether a series of statements by Juniper Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On October 24, 2016, Juniper Pharmaceuticals filed its Form 8-K and revealed that it would be restating its financial statements since 2013, due to errors in its revenue in connection to a supply agreement with an affiliate of Germany's Merck KGaA.

On the news, NASDAQ: JNP dropped 10% in early morning trading on October 25, 2016.

Based in Boston, Massachusetts, and founded in 1986 Juniper Pharmaceuticals Inc develops therapeutics that address unmet medical needs in women's health

If you purchased shares of Juniper Pharmaceuticals Inc (NASDAQ: JNP) on or before October 24, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185